1214ȫʡDI(y)ِܸ——miμِܸ^һµĽAMĻʡ[t(y)ԺDƽot(y)s@ΛQِ˳ɿһȪFwɿһcĿ(ΣЮaDΣͯ۱)ِܸһȪx֣MɰꠅȫQِ
^ʮIJиŬʡ[t(y)ԺDѽɞ鼯Rt(y)̌WһwgȾCίɫcȺГҼn}8헡ʡn}10l(f)SCI 200ƪĺڿ80ƪc10౾OӋ10@ÇҼƼ2ʡƼ3s@ȻƌWʡȻƌW𡢅Aƽt(y)WRЌYȶ헻F(xin)鰲ʡRcʡcWҼʡmiYӖ
İ٘sDƌWƎ^t(y)t(y)WʿʿЇƌWgWʿʮʡWgg^˺xʡһ“꽭t(y)”LڏDt(y)ƌWоRоNDƼmiѳӌmĤꎰȋDƐ[ȷоLD[ľC\κNDgAt(y)WD[WI(y)ίTίTЇt(y)f(xi)DaƷ֕ίTίTЇf(xi)[ȷڌI(y)ίTίTʡf(xi)[ȷڌI(y)ίTίTʡf(xi)µȶWghs@ҼʡƼMһȪ Ȫȶ헪s@At(y)W[W֕“A[ t(y)”ȷQ̖Ϋ@ȫDƸǻRgDMһ Ȫ
DʼKR\ͻAоҕD[\ίڸDƐ[\༰ίȷeSĽԏͰl(f)ѳľCίɫƶЧίγһD[\Ҏ(gu)wϵҿϵѳҎ(gu)\|ԇcģѳ[pgROгʸÿekDƐ[Ҏ(gu)\εćҼ^̰࣬Ո֪nԼgָÿ¾Mоϵgֱпht(y)Ժ^ĦrՈȌMg
_չɫg(1)ѳ[pg漰踹ǻKгÿɽ100_ROг_80%;(2)Ͱl(f)[ǻgg^̏sgy^жǻgA^@[ߵ;(3)miӌmĤѳĸǻRgԼmiӌmĤǰܰͽY@Ӱgÿɼs400_(4)ӌmӌmټѳ[90%Ͼ(chung)ί⣬ڶпڸǻRA_չοǻRԼ(chung)͵_չпڸǻRDÿɼs100ggYֺ(5)ӌmӌmټ̥Pֲ롢ӌmпȟo(chung)ĸߏȾ۽ίԓgĿǰʡȿ_չt(y)ԺHɼĿǰɺί2000PίЧcίA|^(q)̎Iȵλʮ“һһ·”ؾt(y)ͬǰW^RоһĿǰ@Ժn}һl(f)һ헣Ŀl(f)¶ƪ(6)ڼgӌmӌmټYҲV_չDڰʡ_չĿDƼίṩ·²|Ŀǰ600wк黼ίͬroŮԹܡ(7)miίԼmiίÿꎵRz(sh)s2000
DƇ@D[̽_չ¼gԳRͿY2022l(f)һǰհAġα_Ř˺IIо(lin)oίƤѳ̽оȡ^ĽY202310ښW[ȿƌW(ESMO)ϰl(f)}"Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study"ıڈѳoίṩµѭCt(y)WC(j)
Dҕpt(y)B(yng)cLÿλt(y)Ycƶl(f)չҎ(gu)ˌLƄˋDRggȫl(f)չ“СC” l(f)չעrĻĄxMތWȣĿǰxʿҲؓʡ߅^(q)D[t(y)ČӖ΄պ͋D[I(y)оB(yng)΄;ekʡDԲ׃^̰༰hӖ˔(sh)_1000;ݗW(wng)jt(y)ԺʮDƞʡΨһһҌmiӖؓ؟ʡl(wi)ˆTmiιӖc鹤ÿ궨ek4ΌmiӖhʡƏVmiҎ(gu)ӖԼꎵRzҎ(gu)ָӖһӋDat(y)Ҏ(gu)ꎵRz鼰mi\
Dƌڞ黼ṩ“(yu)|Ч”t(y)^m(x)ŬƽOӏCIȫ_I(y)¼g(chung)_չ(wn)M˲Mһ(yu)t(y)CϷ@ͬrҲŬ߰ʡ[\ˮƽؕI
/D
ᾀԒ0551-62620110
eԒ0551-64376913
e]䣺3598612204@qq.com